Christian X. Cruz Pico
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian X. Cruz Pico has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Xiaofeng Zheng
26 shared publicationsFunda Meric-Bernstam
24 shared publications- Ken Chen
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
23 shared publications Ana Maria Gonzalez-Angulo
22 shared publicationsAnil Korkut
22 shared publicationsArgun Akcakanat
22 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 4. ATM IHC and genomics of PDXs treated with elimusertib 40 mg/kg.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 4. ATM IHC and genomics of PDXs treated with elimusertib 40 mg/kg.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 8: PARPi resistant models with response to ATR inhibition.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 8: PARPi resistant models with response to ATR inhibition.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 3. Change in body weight of mice bearing 10 different patient derived xenografts treated with elimusertib 40 mg/kg.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 3. Change in body weight of mice bearing 10 different patient derived xenografts treated with elimusertib 40 mg/kg.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 5: Tolerability of 40 mg/kg elimusertib
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 10: Additional IHC and RPPA results from pharmacodynamic experiments.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 10: Additional IHC and RPPA results from pharmacodynamic experiments.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 1: Characteristics and treatment histories of PDXs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 1: Characteristics and treatment histories of PDXs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 2: Characteristics and treatment histories of PDXs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 2: Characteristics and treatment histories of PDXs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 4: Clinical elimusertib response of coclinical PDXs.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Table 4: Clinical elimusertib response of coclinical PDXs.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Data from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
The ataxia telangiectasia and RAD3-related (ATR) kinase functions with ataxia telangiectasia–mutated (ATM) kinase as a modulator of DNA damage response (DDR). We assessed the antitumor effects of the ATR inhibitor elimusertib (BAY-1895344) in patient-derived xenograft (PDX) models with DDR alterations. Antitumor activity was assessed by change in tumor volume (TV) from baseline. Responses were categorized as follows: partial response (PR), ≥30% decrease in TV; ≥20% increase in TV, progressive disease; and non-PR/progressive disease, stable disease (SD). Event-free survival was defined as time for tumor doubling (EFS-2). Of 21 PDX models tested, 11 had significant prolongation of EFS-2 with elimusertib monotherapy. Four models had a PR and four had SD. PR/SD was observed in two of five models with ATM loss on IHC and in models with a variety of alterations in DDR genes, including BRCA1/2 and ATM. Elimusertib prolonged EFS-2 in three of five models with known PARP inhibitor resistance. Pharmacodynamic studies conducted in four PDX models showed an increase in DNA damage markers. PI3K/mTOR pathway signaling increased in two of four models. The combination of the PI3K inhibitor copanlisib with elimusertib enhanced EFS-2 compared with monotherapy in three of 11 models tested. The combination of elimusertib with the PARP inhibitor niraparib enhanced antitumor activity compared with single agents in PARP-resistant PDX models. Our study shows that ATR inhibition has antitumor activity, including in models with both intrinsic and acquired PARP inhibitor resistance. Further work is needed to better refine patient selection for ATR-based therapies.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
The ataxia telangiectasia and RAD3-related (ATR) kinase functions with ataxia telangiectasia–mutated (ATM) kinase as a modulator of DNA damage response (DDR). We assessed the antitumor effects of the ATR inhibitor elimusertib (BAY-1895344) in patient-derived xenograft (PDX) models with DDR alterations. Antitumor activity was assessed by change in tumor volume (TV) from baseline. Responses were categorized as follows: partial response (PR), ≥30% decrease in TV; ≥20% increase in TV, progressive disease; and non-PR/progressive disease, stable disease (SD). Event-free survival was defined as time for tumor doubling (EFS-2). Of 21 PDX models tested, 11 had significant prolongation of EFS-2 with elimusertib monotherapy. Four models had a PR and four had SD. PR/SD was observed in two of five models with ATM loss on IHC and in models with a variety of alterations in DDR genes, including BRCA1/2 and ATM. Elimusertib prolonged EFS-2 in three of five models with known PARP inhibitor resistance. Pharmacodynamic studies conducted in four PDX models showed an increase in DNA damage markers. PI3K/mTOR pathway signaling increased in two of four models. The combination of the PI3K inhibitor copanlisib with elimusertib enhanced EFS-2 compared with monotherapy in three of 11 models tested. The combination of elimusertib with the PARP inhibitor niraparib enhanced antitumor activity compared with single agents in PARP-resistant PDX models. Our study shows that ATR inhibition has antitumor activity, including in models with both intrinsic and acquired PARP inhibitor resistance. Further work is needed to better refine patient selection for ATR-based therapies.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 2. Tumor volume growth curve and waterfall plots for models shown in Figure 1. Waterfall plot represent day 20 or the last day of control group measurement.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Supplementary Figure 2. Tumor volume growth curve and waterfall plots for models shown in Figure 1. Waterfall plot represent day 20 or the last day of control group measurement.